<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3226">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03064906</url>
  </required_header>
  <id_info>
    <org_study_id>IDE2</org_study_id>
    <nct_id>NCT03064906</nct_id>
  </id_info>
  <brief_title>Insulet Artificial Pancreas Evaluating Meal Performance and Moderate Exercise (IDE2)</brief_title>
  <acronym>IDE2</acronym>
  <official_title>Evaluating Meal Performance and Effect of Moderate Intensity Exercise in Patients With Type 1 Diabetes With the Insulet Automated Glucose Control System: IDE 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Insulet Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Insulet Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and performance of the Insulet AP (artificial pancreas) system, using
      the Omnipod® insulin management system, Dexcom G4 Share® AP System and personalized model
      predictive control algorithm in adults with type 1 diabetes consuming high fat meals and
      undertaking moderate intensity exercise.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The two-part study schedule consists of a 7±1 day outpatient, open-loop phase, followed by
      one 54-hour, hybrid closed-loop phases conducted in a supervised CRC or hotel/rental house
      setting.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 18, 2017</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The two-part study schedule consists of a 7±1 day outpatient, open-loop phase, followed by one 54-hour (Option A - Meal Performance and/or Option B - Exercise), hybrid closed-loop phases conducted in a supervised CRC or hotel/rental house setting. Subjects may participate in hybrid closed-loop session Option A and/or Option B.</intervention_model_description>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of time in hypoglycemic range (defined as &lt; 70 mg/dL)</measure>
    <time_frame>54 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of time in hyperglycemic range(defined as ≥ 250 mg/dL)</measure>
    <time_frame>54 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean glucose</measure>
    <time_frame>54 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of time &lt; 50 mg/dL</measure>
    <time_frame>54 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of time &lt; 60 mg/dL</measure>
    <time_frame>54 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of time &gt; 180 mg/dL</measure>
    <time_frame>54 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of time ≥ 300 mg/dL</measure>
    <time_frame>54 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of time between 70-180 mg/dL</measure>
    <time_frame>54 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of time between 70-140 mg/dL</measure>
    <time_frame>54 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standard deviation</measure>
    <time_frame>54 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coefficient of variation</measure>
    <time_frame>54 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Meal Performance and/or Exercise</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This study is a two-part, multi-center, observational clinical trial being conducted in a Clinical Research Center (CRC) setting using the Insulet AP (artificial pancreas) system.
Subjects may participate in hybrid closed-loop session Option A - Meal Performance and/or Option B - Exercise, but are not required to participate in both. If participating in both, Option A and Option B must be conducted in separate sessions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Insulet AP (artificial pancreas) System</intervention_name>
    <description>Insulet AP (artificial pancreas) system, using the Omnipod® insulin management system, Dexcom G4 Share® AP System and personalized model predictive control algorithm.</description>
    <arm_group_label>Meal Performance and/or Exercise</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age at time of consent 18.0 to 65.0 years

          2. Diagnosed with type 1 diabetes for at least one year. Diagnosis is based on
             investigator's clinical judgment.

          3. Total daily dose (TDD) of insulin ≥0.3 units/kg/day and A1C &gt;6% at screening

          4. Currently using an insulin pump with U-100 rapid-acting insulin analogs and on pump
             therapy for at least 6 months prior to study start

          5. Willing to use the study CGM device for the duration of the study

          6. Willing to use the Omnipod® Insulin Management System during the study

          7. Willing to perform all fingerstick BG testing with the study-approved glucose meter
             at the frequency specified in the study protocol

          8. Willing to abide by meal recommendations for breakfast, lunch and dinner during the
             study

          9. Willing to participate in moderate intensity exercise for up to 45 minutes if taking
             part in Option B

         10. Willing to refrain from use of acetaminophen and supplemental vitamin C (&gt;2000
             mg/daily) for the entire duration of participation in the study

         11. Willing and able to sign the Informed Consent Form (ICF)

        Exclusion Criteria:

          1. A1C &gt;10% at the screening visit

          2. One or more episodes of severe hypoglycemia requiring emergency room (ER) visit or
             hospitalization within the past 6 months

          3. Hypoglycemic unawareness as determined by a score of ≥4 &quot;R&quot; responses on the Clarke
             Questionnaire

          4. One or more episodes of diabetic ketoacidosis requiring ER visit or hospitalization
             within the past 6 months

          5. Used non-insulin anti-diabetic medication within last 30 days

          6. Pregnant or lactating, or is a woman of childbearing potential and not on acceptable
             form of birth control (acceptable includes abstinence, condoms, oral/injectable
             contraceptives, IUD or implant)

          7. Dermatological conditions at the proposed sensor wear sites that in the
             investigator's opinion could preclude ability to wear the Pod and/or the Dexcom
             sensor

          8. Current or known history of cardiovascular disease, arrhythmia, myocardial infarction
             (MI) or stroke. An electrocardiogram (ECG) must be obtained within 6 months.

          9. Currently undergoing systemic treatment with steroids or immunosuppressive medication

         10. Current illness that would interfere with participation in the study

         11. Currently participating in another clinical study using an investigational drug or
             device

         12. Recent (within the preceding 30 days) participation in a clinical study using an
             investigational drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce Buckingham, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trang Ly, MBBS</last_name>
    <email>APClinical@insulet.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniel McCarthy, BS</last_name>
    <email>dmccarthy@insulet.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruce Buckingham, MD</last_name>
      <email>bbendo@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Paula Clinton, RD,CDE</last_name>
      <phone>650-736-2313</phone>
      <email>pclinton@stanford.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Diablo Clinical Research</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Christiansen, MD</last_name>
      <email>mchristiansen@diabloclinical.com</email>
    </contact>
    <contact_backup>
      <last_name>Margie Macarewich</last_name>
      <phone>925-930-7267</phone>
      <email>mmacarewich@diabloclinical.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 3, 2017</lastchanged_date>
  <firstreceived_date>February 22, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>T1D, Omnipod</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pancrelipase</mesh_term>
    <mesh_term>Pancreatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
